News
Dr Santin on the Clinical Activity of Sacituzumab Govitecan in Recurrent Endometrial Cancer
Alessandro Santin, MD, professor, Obstetrics, Gynecology, and Reproductive Sciences, Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center, co-chief, Section of Gynecologic Oncology, discusses the clinical activity of sacituzumab govitecan-hziy (Trodelvy) in patients with recurrent endometrial cancer who overexpress Trop-2.
Preliminary results from stage 1 of a phase 2 trial (NCT04251416) presented at the 2023 ASCO Annual Meeting showed that among 21 patients evaluable for efficacy, the objective response rate was 33.3%, including 1 (4.8%) complete response and 6 (28.5%) partial responses. Additionally, 47.6% of patients had stable disease, and 14.3% experienced progressive disease. Notably, in 20 patients evaluable for disease control, the 6-month durable disease control rate was 35.0%.
Source: OncLive